Effectiveness of Immersive Virtual Reality in Patients With Cancer

Sponsor
ASL Gallura - Ospedale Giovanni Paolo II (Other)
Overall Status
Completed
CT.gov ID
NCT05629507
Collaborator
(none)
74
1
3
4.5
16.3

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to study the effects of Immersive Virtual Reality in patients with cancer undergoing chemotherapy.

The main questions it aims to answer are:
  • Could the immersive virtual reality application prevents or reduces anxiety, prevents or reduces fatigue, prevents or reduces pain, improves therapeutic adherence, prevents or reduces adverse events, then cancer patients treated with narrative medicine, and then cancer patients in standard care only?

  • Could the immersive virtual reality application show symptoms of cybersickness?

Participants will be randomly allocated with balanced allocation ratio 1: 1: 1 into three groups: 1) Virtual Reality group; 2) Narrative medicine group; 3) Standard care group.

In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.

In control arm, patients will be free to choose different activities during the infusion of chemotherapy, such as conversation with nurses, doctors, trainees, reading, writing, watching television, listening to music or videos on their smartphone.

In narrative medicine arm, patients will express their subjective experience regarding to the chemotherapy through writing. The experience will be written in free form by the patient and will cover both the cognitive, emotional and perceptual aspects. A nurse will always be available to guide the patient in the activity of expressing cognitive, emotional and perceptual contents.

Researchers will compare the Virtual Reality group, Narrative Medicine group, Standard care group, to see the effects regarding to anxiety, fatigue, pain, improves therapeutic adherence and adverse events.

Condition or Disease Intervention/Treatment Phase
  • Device: Virtual Reality
N/A

Detailed Description

This study is a three-arms randomized controlled trial that will be conducted at St Giovanni Paolo II Hospital, Olbia (Italy), from July 2022 to November 2022. This RCT, is an open-label trial, longitudinal, pre-post test, with balanced allocation ratio 1: 1: 1, monocentric, in patients with cancer undergoing intravenous chemotherapy.

Patients will be randomly allocated into three groups: 1) Virtual Reality group; 2) Narrative Medicine group; 3) Standard Care group.

Primary outcome is Anxiety, measured with State-Trait Anxiety Inventory. Secondary outcomes are: 1) fatigue measured with Revised Piper Fatigue Scale; 2) pain measured with Visual Analogic Scale; 3) Adverse effects, measured as manifestation of nausea, vomiting, needle phobia; 4) Symptoms of cybersickness will be measured with Reality Symptom Questionnaire.The study will conduct in accordance with the ethical standards as laid down in the Declaration of Helsinki, with the protocol approved by the Ethics Committee (Trial registration number: RS 97/CE). A written informed consent will obtain from all patients included in the study.

In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.The Virtual Reality headset will administer through the use of a Virtual Reality headset.The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo.

The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios).

In control arm, patients will be free to choose different activities during the infusion of chemotherapy, such as conversation with nurses, doctors, trainees, reading, writing, watching television, listening to music or videos on their smartphone.

In narrative medicine arm, patients will express their subjective experience regarding to the chemotherapy through writing. The experience will be written in free form by the patient and will cover both the cognitive, emotional and perceptual aspects. A nurse will always be available to guide the patient in the activity of expressing cognitive, emotional and perceptual contents.

Study Design

Study Type:
Interventional
Actual Enrollment :
74 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effectiveness of Immersive Virtual Reality in Patients With Cancer Undergoing Chemotherapy: a Randomized Controlled Trial
Actual Study Start Date :
Jul 1, 2022
Actual Primary Completion Date :
Oct 30, 2022
Actual Study Completion Date :
Nov 16, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual Reality

In the virtual reality arm, patients will use a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and High Definition audio stereo.

Device: Virtual Reality
The Virtual Reality intervention will administer through the use of a Virtual Reality headset. The multimedia contents in VR, will have a video quality from 4K to 8K, 360 degrees, and HD audio stereo. The scenarios are classified into 12 categories: 1) Artistic cities (60 scenarios); 2) Africa (17 scenarios); 3) Hills (26 scenarios); 4) Rivers, lakes and waterfalls (43 scenarios); 5) Sardinia (13 scenarios); 6) Deserts (21 scenarios); 7) Beaches (20 scenarios); 8) Animals (20 scenarios); 9) Mountains (25 scenarios); 10) Concerts (21 scenarios); 11) Sea (24 scenarios); 12) submarine (20 scenarios).

No Intervention: Narrative Medicine

In narrative medicine arm, patients will express their subjective experience regarding to the chemotherapy through writing. The experience will be written in free form by the patient and will cover both the cognitive, emotional and perceptual aspects. A nurse will always be available to guide the patient in the activity of expressing cognitive, emotional and perceptual contents.

No Intervention: Standard Care

In control arm, patients will be free to choose different activities during the infusion of chemotherapy, such as conversation with nurses, doctors, trainees, reading, writing, watching television, listening to music or videos on their smartphone.

Outcome Measures

Primary Outcome Measures

  1. Change is being assessed for Anxiety [Baseline, pre-intervention and immediately after the intervention]

    Anxiety is assessed with State-Trait Anxiety Inventory.The minimum value is 20 and the maximum value is 80, whether higher scores mean a worsening of anxiety.

Secondary Outcome Measures

  1. Assessment of Fatigue [Baseline, pre-intervention and immediately after the intervention]

    Fatigue is assessed with Revised Piper Fatigue Scale. The minimum value is 0 and the maximum value is 10, whether higher scores mean a worsening of fatigue.

  2. Assessment of Pain [Baseline, pre-intervention and immediately after the intervention]

    Pain is assessed with Visual Analogic Scale.The minimum total score is 0 and the maximum is 10, whether higher scores mean a worsening of pain.

  3. Number of partecipants with Adverse effects [Baseline, pre-intervention and immediately after the intervention]

    Adverse effects are assessed as number of partecipants with nausea, vomiting, needle phobia.

  4. Number of partecipants with a therapeutic adherence [Baseline, pre-intervention and immediately after the intervention]

    The therapeutic adherence is assessed as number of partecipants with a reduction,delay, or discontinuation of chemotherapy administration.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age> 18 years;

  • diagnosis of cancer with indication for intravenous chemotherapy;

  • cognitively able to participate;

  • no significant acoustic deficit;

  • no significant visual impairment;

  • sufficient ability to write and read in Italian.

Exclusion Criteria:
  • use of antipsychotic drugs;

  • epilepsy;

  • use of drugs or alcohol;

  • metastatic cancer.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Salvatore Ortu Olbia Sassari Italy 07026

Sponsors and Collaborators

  • ASL Gallura - Ospedale Giovanni Paolo II

Investigators

  • Principal Investigator: Salvatore Ortu, Dr, Oncology Unit, Giovanni Paolo II Hospital, Olbia,Italy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Salvatore Ortu, Principal Investigator, ASL Gallura - Ospedale Giovanni Paolo II
ClinicalTrials.gov Identifier:
NCT05629507
Other Study ID Numbers:
  • VROM_01
First Posted:
Nov 29, 2022
Last Update Posted:
Nov 29, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Salvatore Ortu, Principal Investigator, ASL Gallura - Ospedale Giovanni Paolo II
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2022